(Q35609748)

9 August 2017

1 reference

title

Safety of GnRH agonists and antagonists (English)

1 reference

9 August 2017

Basil C Tarlatzis

1

1 reference

9 August 2017

Helen Bili

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Drug Safety

9 August 2017

published in

1 reference

9 August 2017

volume

3

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

39-46

1 reference

Gonadotropin-releasing-hormone-receptor antagonists

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

The use of GnRH antagonists in ovarian stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Efficacy of nafarelin in assisted reproductive technology: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Controlled ovarian hyperstimulation in assisted reproduction: effect on the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle-stimulating hormone containing the human chorionic gonadotropin carboxyterminal peptide in the rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

GnRH antagonist in assisted reproduction: a Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2----p21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Gonadotropin-releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Specific binding of gonadotrophin-releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties, and luteal phase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Prospective follow-up study of 877 children born after intracytoplasmic sperm injection (ICSI), with ejaculated epididymal and testicular spermatozoa and after replacement of cryopreserved embryos obtained after ICSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Deliveries and children born after in-vitro fertilisation in Sweden 1982-95: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

A Danish national cohort of 730 infants born after intracytoplasmic sperm injection (ICSI) 1994-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Danish National In-Vitro Fertilization Registry 1994 and 1995: a controlled study of births, malformations and cytogenetic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

The influence of inadvertent intranasal buserelin administration in early pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Long term follow-up of children born after inadvertent administration of a GnRH-analogue in early pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

Developmental outcome at 2 years of age for children born after ICSI compared with children born after IVF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.39

21 January 2018

Identifiers

DOI

10.1517/14740338.3.1.39

1 reference

9 August 2017

1 reference